MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Mario Martínez Soldevilla 1,2 , Helena Villanueva 1,2 , Noelia Casares 2,3 , Juan Jose Lasarte 2,3 , Maurizio Bendandi 4 , Susana Inoges 2,5 , Ascensión López-Díaz de Cerio 2,5 and Fernando Pastor 1,2 1 Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain 2 Instituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de Navarra, Irunlarrea, Pamplona, Spain 3 Program Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain 4 Ross University School of Medicine, Roseau, Portsmouth, Commonwealth of Dominica 5 Clínica Universidad de Navarra, Pamplona, Spain Correspondence to: Fernando Pastor, email: // Keywords : aptamer, cancer immunotherapy, costimutaltion, targeting Received : February 23, 2016 Accepted : February 28, 2016 Published : March 15, 2016 Abstract In this work we show a clinically feasible strategy to convert in situ the own tumor into an endogenous vaccine by coating the melanoma cancerous cells with CD28 costimulatory ligands. This therapeutic approach is aimed at targeting T-cell costimulation to chemotherapy-resistant tumors which are refractory and been considered as untreatable cancers. These tumors are usually defined by an enrichment of cancer stem cells and characterized by the higher expression of chemotherapy-resistant proteins. In this work we develop the first aptamer that targets chemotherapy-resistant tumors expressing MRP1 through a novel combinatorial peptide-cell SELEX. With the use of the MRP1 aptamer we engineer a MRP1-CD28 bivalent aptamer that is able to bind MRP1-expressing tumors and deliver the CD28 costimulatory signal to tumor-infiltrating lymphocytes. The bi-specific aptamer is able to enhance costimulation in chemotherapy-resistant tumors. Melanoma-bearing mice systemically treated with MRP1-CD28 bivalent aptamer show reduced growth, thus proving an improved mice survival. Besides, we have designed a technically feasible and translational whole-cell vaccine (Aptvax). Disaggregated cells from tumors can be directly decorated with costimulatory ligand aptamers to generate the vaccine Aptvax. CD28Aptvax made of irradiated tumor cells coated with the CD28-agonistic aptamer attached to MRP1 elicits a strong tumor- cell immune response against melanoma tumors reducing tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 3×
“But, at the same time, it is an up-regulated marker on cancer stem cells, which are precisely the cells that are more resistant to chemotherapy and radiotherapy and, therefore, the ones responsible for tumor relapse in the long term [15].”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 11×
“Multidrug Resistant-associated Protein 1 (MRP1) has been directly correlated with chemotherapy drug resistance in several types of tumors [4, 7-10], and, along with other chemotherapy-resistant proteins, it is highly expressed in cancer stem cells [11-13].”
BackgroundMethodInfluentialEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 2×
“It has previously been confirmed by other groups that chemotherapy resistance is associated with the enrichment of cancer stem cells [14, 15].”
BackgroundCD28-mediated co-stimulation: a quantitative support for TCR signalling.
Acuto, O., & Michel, F. (2003) · Nature Reviews Immunology · doi:10.1038/nri1248 · Cited by 775 · cited 1×
“CD28 has been underscored as one of the major costimulatory receptors on T lymphocytes, promoting proliferation and cell differentiation into effector T cells [17].”
BackgroundMoitra, K., Lou, H., & Dean, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.14 · Cited by 279 · cited 2×
“As drug resistance has been associated with cancer stem cells [13], we reasoned that the MRP1Apt could be used to enrich a subpopulation of cancer stem cells.”
Background
Cited by
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
An RNA toolbox for cancer immunotherapy
Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Mercier, M.-C., Dontenwill, M., & Choulier, L. (2017) · Cancers · doi:10.3390/cancers9060069 · Cited by 113
“[111] used another variant of reverse hybrid-SELEX, combining cell-SELEX to peptide-SELEX.”
Method
Metadata
- Authors
- Soldevilla, M. M., Villanueva, H., Casares, N., Lasarte, J. J., Bendandi, M., Inoges, S., de Cerio, A. L.-D., & Pastor, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-15
- Volume
- 7
- Issue
- 17
- Pages
- 23182-23196
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2343194692
- Cited by
- 68
- References
- 5
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.